Evidence map›Paper›PMID 34165728›Full record

Observational studyTranslational stroke research2022

Neurological Instability in Ischemic Stroke: Relation with Outcome, Latency Time, and Molecular Markers.

Ramón Iglesias-Rey, Andres da Silva-Candal, Manuel Rodríguez-Yáñez, Ana Estany-Gestal, Uxía Regueiro, Elena Maqueda, Paulo Ávila-Gómez, José Manuel Pumar, José Castillo, Tomás Sobrino and 2 more

Open access · hybridAbstract readObservational Study
In one paragraph

Observational study in Translational stroke research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Associations between admission levels of multiple biomarkers and subsequent worse outcomes in acute ischemic stroke patients.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2024
    Article
  3. Article
  4. Advancement of epigenetics in stroke.Frontiers in neuroscience · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Ramón Iglesias-ReyClinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), 15706, Santiago de Compostela, Spain. ramon.iglesias.rey@sergas.es.
Andres da Silva-CandalClinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), 15706, Santiago de Compostela, Spain.
Manuel Rodríguez-YáñezStroke Unit, Department of Neurology, Hospital Clínico Universitario, Santiago de Compostela, Spain.
Ana Estany-GestalUnit of Methodology of the Research, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
Uxía RegueiroClinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), 15706, Santiago de Compostela, Spain.
Elena MaquedaClinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), 15706, Santiago de Compostela, Spain.
Paulo Ávila-GómezClinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), 15706, Santiago de Compostela, Spain.
José Manuel PumarDepartment of Neuroradiology, Hospital Clínico Universitario, Santiago de Compostela, Spain.
José CastilloClinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), 15706, Santiago de Compostela, Spain.
Tomás SobrinoClinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), 15706, Santiago de Compostela, Spain.
Francisco CamposClinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), 15706, Santiago de Compostela, Spain.
Pablo HervellaClinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), 15706, Santiago de Compostela, Spain. pablo.hervella.lorenzo@sergas.es.ORCID 0000-0003-1249-6333
Instituto de Investigación Sanitaria de Santiago · ESComplejo Hospitalario Universitario de Santiago · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The National Institutes of Health Stroke Scale (NIHSS) is commonly used to evaluate stroke neurological deficits and to predict the patient's outcome. Neurological instability (NI), defined as the variation of the NIHSS in the first 48 h, is a simple clinical metric that reflects dynamic changes in the area of the brain affected by the ischemia. We hypothesize that NI may represent areas of cerebral instability known as penumbra, which could expand or reduce brain injury and its associated neurological sequels. In this work, our aim was to analyze the association of NI with the functional outcome at 3 months and to study clinical biomarkers associated to NI as surrogate biomarkers of ischemic and inflammatory penumbrae in ischemic stroke (IS) patients. We included 663 IS patients in a retrospective observational study. Neutral NI was defined as a variation in the NI scale between - 5 and 5% (37.1%). Positive NI is attributed to patients with an improvement of > 5% NI after 48 h (48.9%), while negative NI is assigned to patients values lower than - 5% (14.0%). Poor outcome was assigned to patients with mRS ≥ 3 at 3 months. We observed an inverse association of poor outcome with positive NI (OR, 0.35; 95%CI, 0.18-0.67; p = 0.002) and a direct association with negative NI (OR, 6.30; 95%CI, 2.12-18.65; p = 0.001). Negative NI showed a higher association with poor outcome than most clinical markers. Regarding good functional outcome, positive NI was the marker with the higher association (19.31; CI 95%, 9.03-41.28; p < 0.0001) and with the highest percentage of identified patients with good functional outcome (17.6%). Patients with negative NI have higher glutamate levels compared with patients with neutral and positive NI (p < 0.0001). IL6 levels are significantly lower in patients with positive NI compared with neutral NI (p < 0.0001), while patients with negative NI showed the highest IL6 values (p < 0.0001). High glutamate levels were associated with negative NI at short latency times, decreasing at higher latency times. An opposite trend was observed for inflammation, and IL6 levels were similar in patients with positive and negative NI in the first 6 h and then higher in patients with negative NI. These results support NI as a prognosis factor in IS and the hypothesis of the existence of a delayed inflammatory penumbra, opening up the possibility of extending the therapeutic window for IS.

Indexed as

Brain IschemiaIschemic StrokeStrokeBiomarkersGlutamatesHumansInterleukin-6IschemiaTreatment OutcomeBiomarkersGlutamatesInterleukin-6GlutamateInterleukinLatency timeNeurological instabilityStroke

Identifiers

PMID34165728
PMCPMC8918467
OpenAlexW3175462413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.